These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20870258)

  • 1. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection.
    Hailu W; Weldegebreal T; Hurissa Z; Tafes H; Omollo R; Yifru S; Balasegaram M; Hailu A
    Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):706-12. PubMed ID: 20870258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
    Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection].
    Santos J; Rivero A; Márquez M
    An Med Interna; 2000 Oct; 17(10):562-3. PubMed ID: 11109659
    [No Abstract]   [Full Text] [Related]  

  • 5. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
    Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral leishmaniasis.
    Berhe N; Abraham Y; Hailu A; Ali A; Mengistu G; Tsige K; Abebe Y
    East Afr Med J; 2001 Nov; 78(11):608-10. PubMed ID: 12219968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil.
    Oliveira AL; Brustoloni YM; Fernandes TD; Dorval ME; Cunha RV; Bóia MN
    Trop Doct; 2009 Jul; 39(3):180-2. PubMed ID: 19535762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)].
    Barthet M; Brunet P; Bernard JC; Dussol B; Rodor F; Jouglard J; Berland Y; Sahel J
    Gastroenterol Clin Biol; 1994; 18(1):90-2. PubMed ID: 8187998
    [No Abstract]   [Full Text] [Related]  

  • 9. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
    Bermúdez H; Rojas E; Garcia L; Desjeux P; Dujardin JC; Boelaert M; Chappuis F
    Ann Trop Med Parasitol; 2006 Oct; 100(7):591-600. PubMed ID: 16989685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
    Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
    Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children.
    Shahian M; Alborzi A
    Med Sci Monit; 2009 Jun; 15(6):CR290-3. PubMed ID: 19478699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia.
    Hurissa Z; Gebre-Silassie S; Hailu W; Tefera T; Lalloo DG; Cuevas LE; Hailu A
    Trop Med Int Health; 2010 Jul; 15(7):848-55. PubMed ID: 20487426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meglumine antimoniate-induced pancreatitis.
    Torrús D; Massa B; Boix V; Portilla J; Pérez-Mateo M
    Am J Gastroenterol; 1996 Apr; 91(4):820-1. PubMed ID: 8677970
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R; Handjani F; Nouhpisheh MK
    J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nephrotic syndrome and acute pancreatitis related to glucantime administration].
    Valencia ME; Laguna F; González Lahoz J
    An Med Interna; 2000 Jan; 17(1):54. PubMed ID: 10730416
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
    Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
    Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute pancreatitis due to antimonials in patients with visceral leishmaniasis and HIV infection].
    Cortés E; Ribera E; Cucurull E; de Otero J; Ocaña I; Pahissa A
    Med Clin (Barc); 1995 Apr; 104(15):578-80. PubMed ID: 7769868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
    Kimutai R; Musa AM; Njoroge S; Omollo R; Alves F; Hailu A; Khalil EA; Diro E; Soipei P; Musa B; Salman K; Ritmeijer K; Chappuis F; Rashid J; Mohammed R; Jameneh A; Makonnen E; Olobo J; Okello L; Sagaki P; Strub N; Ellis S; Alvar J; Balasegaram M; Alirol E; Wasunna M
    Clin Drug Investig; 2017 Mar; 37(3):259-272. PubMed ID: 28066878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allopurinol in the treatment of American cutaneous leishmaniasis.
    Martinez S; Marr JJ
    N Engl J Med; 1992 Mar; 326(11):741-4. PubMed ID: 1738379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.